ZELLUNA ASA (ZLNA.OL) Stock Fundamental Analysis

OSL:ZLNA • NO0013524942

15.848 NOK
-0.11 (-0.66%)
Last: Feb 13, 2026, 11:21 AM
Fundamental Rating

3

Overall ZLNA gets a fundamental rating of 3 out of 10. We evaluated ZLNA against 81 industry peers in the Biotechnology industry. ZLNA has a great financial health rating, but its profitability evaluates not so good. ZLNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ZLNA had negative earnings in the past year.
  • In the past year ZLNA has reported a negative cash flow from operations.
  • ZLNA had negative earnings in each of the past 5 years.
  • ZLNA had a negative operating cash flow in each of the past 5 years.
ZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -269.09%, ZLNA is not doing good in the industry: 91.36% of the companies in the same industry are doing better.
  • ZLNA has a worse Return On Equity (-337.63%) than 62.96% of its industry peers.
Industry RankSector Rank
ROA -269.09%
ROE -337.63%
ROIC N/A
ROA(3y)-86.89%
ROA(5y)-61.71%
ROE(3y)-116.09%
ROE(5y)-80.15%
ROIC(3y)N/A
ROIC(5y)N/A
ZLNA.OL Yearly ROA, ROE, ROICZLNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • ZLNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZLNA.OL Yearly Profit, Operating, Gross MarginsZLNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ZLNA has about the same amount of shares outstanding.
  • Compared to 5 years ago, ZLNA has more shares outstanding
  • ZLNA has a worse debt/assets ratio than last year.
ZLNA.OL Yearly Shares OutstandingZLNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ZLNA.OL Yearly Total Debt VS Total AssetsZLNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 7.95 indicates that ZLNA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.95, ZLNA belongs to the top of the industry, outperforming 83.95% of the companies in the same industry.
  • There is no outstanding debt for ZLNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.95
ROIC/WACCN/A
WACCN/A
ZLNA.OL Yearly LT Debt VS Equity VS FCFZLNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • ZLNA has a Current Ratio of 3.56. This indicates that ZLNA is financially healthy and has no problem in meeting its short term obligations.
  • ZLNA has a Current ratio of 3.56. This is in the better half of the industry: ZLNA outperforms 67.90% of its industry peers.
  • A Quick Ratio of 3.56 indicates that ZLNA has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.56, ZLNA is in the better half of the industry, outperforming 72.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.56
ZLNA.OL Yearly Current Assets VS Current LiabilitesZLNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 10.78% over the past year.
EPS 1Y (TTM)10.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 34.81% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.02%
EPS Next 2Y34.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZLNA.OL Yearly Revenue VS EstimatesZLNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2M 4M 6M 8M
ZLNA.OL Yearly EPS VS EstimatesZLNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZLNA. In the last year negative earnings were reported.
  • Also next year ZLNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZLNA.OL Price Earnings VS Forward Price EarningsZLNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLNA.OL Per share dataZLNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ZLNA's earnings are expected to grow with 34.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for ZLNA!.
Industry RankSector Rank
Dividend Yield 0%

ZELLUNA ASA

OSL:ZLNA (2/13/2026, 11:21:27 AM)

15.848

-0.11 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-12
Inst Owners15.42%
Inst Owner ChangeN/A
Ins Owners0.72%
Ins Owner ChangeN/A
Market Cap400.95M
Revenue(TTM)5.00K
Net Income(TTM)-212.87M
Analysts42.22
Price Target25.5 (60.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80190.88
P/FCF N/A
P/OCF N/A
P/B 6.36
P/tB 8.68
EV/EBITDA N/A
EPS(TTM)-38.7
EYN/A
EPS(NY)-7.96
Fwd EYN/A
FCF(TTM)-6.2
FCFYN/A
OCF(TTM)-5.95
OCFYN/A
SpS0
BVpS2.49
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -269.09%
ROE -337.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.89%
ROA(5y)-61.71%
ROE(3y)-116.09%
ROE(5y)-80.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.92%
Cap/Sales 125260%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.56
Quick Ratio 3.56
Altman-Z 7.95
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.96%
Cap/Depr(5y)41.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.69%
EPS Next Y89.02%
EPS Next 2Y34.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.76%
OCF growth 3YN/A
OCF growth 5YN/A

ZELLUNA ASA / ZLNA.OL FAQ

What is the ChartMill fundamental rating of ZELLUNA ASA (ZLNA.OL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZLNA.OL.


Can you provide the valuation status for ZELLUNA ASA?

ChartMill assigns a valuation rating of 1 / 10 to ZELLUNA ASA (ZLNA.OL). This can be considered as Overvalued.


What is the profitability of ZLNA stock?

ZELLUNA ASA (ZLNA.OL) has a profitability rating of 0 / 10.


How financially healthy is ZELLUNA ASA?

The financial health rating of ZELLUNA ASA (ZLNA.OL) is 8 / 10.


What is the expected EPS growth for ZELLUNA ASA (ZLNA.OL) stock?

The Earnings per Share (EPS) of ZELLUNA ASA (ZLNA.OL) is expected to grow by 89.02% in the next year.